Format

Send to

Choose Destination
Drug Discov Today. 2016 Jan;21(1):180-189. doi: 10.1016/j.drudis.2015.10.012. Epub 2015 Oct 23.

Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.

Author information

1
Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Vladimir Prelog Weg 1-5/10, CH-8093 Zürich, Switzerland.
2
Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Vladimir Prelog Weg 1-5/10, CH-8093 Zürich, Switzerland. Electronic address: neri@pharma.ethz.ch.

Abstract

Antibody-cytokine fusion proteins, often referred to as immunocytokines, represent a novel class of biopharmaceutical agents that combine the disease-homing activity of certain antibodies with the immunomodulatory properties of cytokine payloads. Originally, immunocytokines were mainly developed for cancer therapy applications. More recently, however, the use of anti-inflammatory cytokines for the treatment of chronic inflammatory conditions and to treat autoimmune diseases has been considered. This review analyzes basic principles in the design of immunocytokines and describes the most advanced products in preclinical and clinical development.

PMID:
26526566
PMCID:
PMC5144993
DOI:
10.1016/j.drudis.2015.10.012
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center